Exposure to AVGAS or petroleum products containing benzene

Acute myeloid leukaemia - Exposure to AVGAS or petroleum products containing benzene Factor

Last reviewed for CCPS 08 January 2007.

Investigative Documents

Claimant Report - Exposure AVGAS or Petroleum Products Containing Benzene - Acute Myeloid Leukaemia [CR9038]

Preliminary questions [11066]

11068

there is some evidence that exposure to AVGAS or petroleum products containing benzene may be a factor in the development of the condition under consideration.

11069 — the veteran has established the causal connection between exposure to AVGAS or petroleum products containing benzene and VEA service for the clinical onset of acute myeloid leukaemia.

11070 — the veteran has established the causal connection between exposure to AVGAS or petroleum products containing benzene and operational service for the clinical onset of acute myeloid leukaemia.

or

11071 — the veteran has established the causal connection between exposure to AVGAS or petroleum products containing benzene and eligible service for the clinical onset of acute myeloid leukaemia.

Clinical onset and operational service [11070]

11073 the veteran experienced inhalation, ingestion or cutaneous contact with AVGAS or petroleum products containing benzene greater than 5 percent by volume on more days than not over a continuous period of at least three months.

22571

where the veteran experienced inhalation, ingestion or cutaneous contact with AVGAS or petroleum products containing benzene greater than 5 percent by volume on more days than not over a continuous period of at least three months, the first exposure occurred at least 5 years before the clinical onset of acute myeloid leukaemia.

11238

operational service made a material contribution to the veteran experiencing inhalation, ingestion or cutaneous contact with AVGAS or petroleum products containing benzene greater than 5 percent by volume on more days than not over a continuous period of at least three months where the first exposure occurred at least 5 years before the clinical onset of acute myeloid leukaemia.

Clinical onset and eligible service [11071]

11081

the veteran experienced inhalation, ingestion or cutaneous contact with AVGAS or petroleum products containing benzene greater than 5 percent by volume on more days than not over a continuous period of at least six months.

22573

where the veteran experienced inhalation, ingestion or cutaneous contact with AVGAS or petroleum products containing benzene greater than 5 percent by volume on more days than not over a continuous period of at least six months, the first exposure occurred at least 10 years before the clinical onset of acute myeloid leukaemia.

11240

eligible service made a material contribution to the veteran experiencing inhalation, ingestion or cutaneous contact with AVGAS or petroleum products containing benzene greater than 5 percent by volume on more days than not over a continuous period of at least six months where the first exposure occurred at least 10 years before the clinical onset of acute myeloid leukaemia.